Vivalis claimed that the EB66 cell line, derived from avian embryonic stem cells, presents characteristics such as genetic stability, immortality and cell growth up to high cell densities in suspension using serum-free media.
EB66 cells replicate human and animal viruses and are currently used for the production of investigational viral vaccines by many vaccine developers.
Vivalis co-managers CEO Franck Grimaud and CSO Majid Mehtali said that the new research license is the third license or sublicense with vaccine Japanese companies signed in this country these last months.
"With six new EB66 licenses signed since the beginning of the year, we are convinced that we will reach the objective of seven new licenses before the end of 2010," Grimaud and Mehtali said.